Overcoming the Inexpressible: How cell-free protein synthesis solved the E. coli toxicity hurdle


In this webinar Prof. Joleen Masschelein from VIB/ KU Leuven in Belgium, shares their experience using the eProtein Discovery platform to produce a difficult-to-express protein that has evaded all other attempts at expression. Prof. Masschelein will discuss their work on natural products produced by bacteria and the potential for new antibiotics and anticancer treatments.

The eProtein Discovery enabled the team to optimize the expression conditions for an GCN5-Related N-Acetyltransferase protein and gain insights into its antibiotic resistance mechanism. The platform provides an efficient and streamlined approach to protein expression, characterization, and purification.

Sign up:

About Prof. Joleen Masschelein and her lab, VIB-KU Leuven:

We study and engineer host-associated bacteria and their specialized metabolites for in vivo therapeutic and agrochemical applications. We are particularly interested in discovering new bioactive natural products from host-associated bacteria elucidating unusual pathways for natural product biosynthesis unravelling the ecological role and mode of action of natural products microbiome engineering for the production of high-value natural products and other therapeutic applications

Our work is multidisciplinary, combining molecular microbiology, synthetic biology, structural biology, metabolomics, enzymology, bioinformatics, analytical chemistry and chemical synthesis.


About eProtein Discovery


Nuclera's eProtein Discovery platform combines digital microfluidic droplet automation with cell-free protein synthesis technologies, it empowers protein scientists to identify the best conditions for expressing and purifying proteins of interest within 24 hours, all on a single consumable cartridge.

The system offers a significant advantage over traditional protein expression methods, allowing researchers to save time and resources by simplifying and automating the process. Its ability to handle multiple genes and customizable cell-free blends makes it a valuable tool for protein scientists in academia and the biopharma industry.